You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Article metrics

Article menu
Clinical trials monitor
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

 

Online download statistics by month:

Online download statistics by month: March 2022 to July 2025

AbstractFullPdf
Mar 2022519528183
Apr 2022268276110
May 202219519675
Jun 202221622286
Jul 202216016154
Aug 202218818846
Sep 202218719059
Oct 202219920150
Nov 202214714764
Dec 202211311345
Jan 202310110223
Feb 202312612663
Mar 202313813991
Apr 2023868675
May 2023949750
Jun 202311211442
Jul 202314514773
Aug 202315815957
Sep 2023888844
Oct 202310710767
Nov 202310810856
Dec 202313213384
Jan 202414814892
Feb 202411211260
Mar 2024198203108
Apr 202413413489
May 202412112388
Jun 202412913175
Jul 202416316375
Aug 2024969555
Sep 2024898967
Oct 202410610775
Nov 202412312482
Dec 202413013197
Jan 202510610763
Feb 2025301304110
Mar 2025969642
Apr 202513013061
May 2025868761
Jun 2025919128
Jul 2025110
Total594760042825